Vaccine

Ontario’s Measles Outbreak Requires Much More Visible & Effective Public Health Response

TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- The Ontario Health Coalition is raising concerns about the sharp increase in people…

10 months ago

Qnovia, Inc. Announces Leadership Transition and Strategic Appointments to Support UK Commercialization Strategy

Mario Danek Appointed President and CEO; James Watson Joins as COO, Francesca Lanuza Appointed Director of Regulatory Affairs, and Dr.…

10 months ago

Evaxion to present at World Vaccine Congress

Congress will take place April 21-24, 2025, in Washington, D.C.COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX)…

10 months ago

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025

Highlights will include data from non-clinical and real-world patient useBOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a…

10 months ago

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting…

10 months ago

NOVA’s Concierge Medicine Boom is a Game Changer for Patients

CHICAGO, April 10, 2025 /PRNewswire/ -- Home to some of the nation's most renowned hospitals and healthcare research centers, Northern…

10 months ago

ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer

Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infectionsStudy…

10 months ago

ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO

HELSINKI and NAPLES, Italy, April 09, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable…

10 months ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine…

10 months ago